There are two wildly different views on how the federal government has classified cannabidiol (CBD) with a new drug code for marijuana extracts:
It was a mere administrative maneuver meant to bring the U.S. in line with international drug control treaties and to better track medical research.
It was the opening salvo in a federal offensive against the emerging American hemp industry.
A proposed final rule notice posted to the Federal Register last December by the U.S. Drug Enforcement Administration established a Controlled Substances Code Number for “marihuana extracts.” The rule notice, which was finalized in January, maintained cannabis-derived extracts’ Schedule I status under the Controlled Substances Act (CSA).
What the DEA saw as innocuous, the hemp industry saw as an existential threat.